The SNP of HLA-DQ is associated with HCC in chronic HBV infection
AASLD LiverLearning®. Yoshioka K. Nov 14, 2016; 144703
Label: Hepatitis B: Epidemiology & Natural History
Dr. Kentaro Yoshioka
Dr. Kentaro Yoshioka
Login now to access Regular content available to all registered users.

AASLD Members enjoy free LiverLearning® Premium Access. Registrants of The Liver Meeting® receive LiverLearning® Premium Access for one year from the first day of the meeting. A LiverLearning® Subscription ($150.00 US) grants access to LiverLearning® Premium content for one year after date of purchase. Click here to purchase your Premium Access Subscription now.

Abstract
Discussion Forum (0)
Rate & Comment (0)
ABSTRACT FINAL ID: 1811

TITLE: The SNP of HLA-DQ is associated with HCC in chronic HBV infection

SPONSORSHIP - THIS STUDY WAS SPONSORED BY: (IF THIS ABSTRACT WAS NOT SPONSORED PLEASE INDICATE):
This abstract was not sponsored.

ABSTRACT BODY:
Background and Aim: Genome-wide association studies (GWAS) revealed that single nucleotide polymorphism (SNP) of HLA-DQ (rs2856718 and rs7453920) is associated with clearance of the HBs antigen in acute HBV infection. However there are a few reports on the effects of the SNPs in the patients with chronic HBV infection. We examined the effects of the SNPs on HCC development and markers of HBV in the patients with chronic HBV infection. Methods: The SNPs of HLA-DP (rs2856718 and rs7453920) were determined in 299 patients with chronic HBV infection, and their associations with clinical characteristics were assessed. The study was approved by the ethics committee of our university and was conducted in accordance with the Declaration of Helsinki. All patients who participated in the study provided written informed consent. Results: In all 299 patients, patients with rs7453920 genotype GG had a significantly higher prevalence of HBV genotype C (p = 0.0045) and a significantly lower prevalence of wild-type basal core promoter (BCP) region than those with genotype AA + AG (p = 0.0462). In 75 HBeAg-positive patients, patients with rs2856718 genotype AG + GG had a significantly lower prevalence of wild-type BCP region than those with genotype AA (p = 0.0180). In 224 HBeAg-negative patients, patients with rs2856718 genotype AG + GG had significantly lower hepatitis B core-related antigen (HBcrAg) levels (p = 0.0184), less frequent treatment with nucleotide/nucleoside analogs (NAs) (p = 0.0433), and less frequent development of hepatocellular carcinoma (HCC) (p = 0.0256) than those with genotype AA. In HBeAg-negative patients, patients with rs7453920 genotype GG had significantly lower HBsAg levels (p < 0.0001), a significantly higher prevalence of HBV genotype C (p = 0.0063), a significantly lower prevalence of wild-type BCP region (p = 0.0045), and a significantly higher prevalence of a family history of chronic HBV infection (p = 0.0147) than those with genotype AA + AG, respectively.
Conclusions: G allele of rs2856718 was associated with lower HBcrAg levels, less frequent treatment with NAs, and less frequent development of HCC in HBeAg-negative patients. These findings correspond with the previous reports that G allele of rs2856718 decreases risk of HCC development. We also demonstrated that A allele of rs7453920 is associated with higher HBsAg levels in HBeAg-negative patients. This finding seems to be contrary to the previous reports that A allele of rs7453920 are acting in favor of clearance of HBs antigen in acute HBV infection. This inconsistency may be attributed to the difference of the phase of infection.

Code of conduct/disclaimer available in General Terms & Conditions